Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Yttrium 90 glass microspheres Clear all
Completed Phase 1Phase 2 Interventional

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

NCT00493883
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Neoplasms
Interventions
yttrium Y 90 microspheres (TheraSphere®)
Device
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 4, 2026, 10:11 PM EDT
Terminated No phase listed Observational

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

NCT03516695
View directory record Official record
Conditions
Liver Cancer
Interventions
TheraSphere®
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 4, 2026, 10:11 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

NCT00739167
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 4, 2026, 10:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

NCT06432036
View directory record Official record
Conditions
Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Interventions
Angiogram, Biospecimen Collection, Computed Tomography, Radioembolization, Single Photon Emission Computed Tomography, Survey Administration, Yttrium Y 90 Glass Microspheres
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 10:11 PM EDT
Completed Phase 3 Interventional

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

NCT00109954
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin, brachytherapy, yttrium Y 90 glass microspheres
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 4, 2026, 10:11 PM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 10:11 PM EDT
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 10:11 PM EDT
Completed Not applicable Interventional

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

NCT01176604
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Yttrium Y 90 Glass Microspheres
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 4, 2026, 10:11 PM EDT
No Longer Available No phase listed Expanded access

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT00589030
View directory record Official record
Conditions
Liver Cancer
Interventions
brachytherapy, yttrium Y 90 glass microspheres
Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 4, 2026, 10:11 PM EDT
Withdrawn Phase 2 Interventional

Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

NCT00039078
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Allan Tsung
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 4, 2026, 10:11 PM EDT
Active, not recruiting Not applicable Interventional

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Interventions
EYE90 Microspheres Treatment
Device
Lead sponsor
ABK Biomedical
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Tucson, Arizona • Orange, California • Altamonte Springs, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 4, 2026, 10:11 PM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 4, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional

Defining the Ablative Dose for Y-90 TARE

NCT07586046
View directory record Official record
Conditions
HCC - Hepatocellular Carcinoma
Interventions
Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 10:11 PM EDT